Schambach H, Nitschke U
Monatsschr Kinderheilkd. 1985 Jan;133(1):32-7.
The international literature shows that the constitutional tall stature of girls has so far been treated with high estrogen doses after the onset of puberty. But nowadays it is felt however, that the potential risks of high-dose estrogen therapy are considerable. While the hazards of persisting gonadotropine suppression were found to be less important, thrombo-embolic complications or severe changes in the liver cannot be excluded in young people. Epidemiological findings and animal experiments suggest that these complications are dose-dependent. In search of an alternative to high-dose treatment, we--from 1966-1980 and basing on Whitelaw--administered approximately physiologic estrogen doses (80 micrograms of mestranol per day for 21 days, plus 2 mg of chlormadinonacetate per day for 10 days, cyclically) to a total of 86 tall girls ranging in age from 9 to 13 years. Only the group of the 20 girls with a skeletal age of 9-10 years, who were still prepubertal at the beginning of therapy, revealed a satisfactory mean height reduction of 7.6 cm. Serious side-effects of therapy did not occur. The possible drastic reduction of the estrogen dose to about 1/4 of the daily dose or about 1/3 of the overall dose as compared to the conventional method allows us to conclude that the early start of treatment offers a true alternative to the high-dose estrogen therapy of the female tall stature.
国际文献表明,迄今为止,对于青春期开始后身材高大的女孩,一直采用高剂量雌激素进行治疗。然而如今人们认为,高剂量雌激素疗法存在相当大的潜在风险。虽然持续抑制促性腺激素的危害相对较小,但年轻人仍无法排除血栓栓塞并发症或肝脏严重病变的风险。流行病学研究结果和动物实验表明,这些并发症与剂量相关。为寻找高剂量治疗的替代方法,我们在1966年至1980年期间,以怀特洛的研究为基础,对86名年龄在9至13岁的身材高大女孩,给予大约生理剂量的雌激素(炔雌醇80微克/天,共21天,加氯地孕酮2毫克/天,共10天,循环给药)。只有开始治疗时仍未进入青春期、骨骼年龄为9至10岁的20名女孩组成的组,平均身高有令人满意的降低,达7.6厘米。治疗未出现严重副作用。与传统方法相比,雌激素剂量可能大幅降至每日剂量的约1/4或总剂量的约1/3,这使我们得出结论,早期开始治疗为女性身材高大的高剂量雌激素疗法提供了一种真正的替代方法。